PGEN

4.2101.20%
HS

Helen Sabzevari

President, CEO & Director

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation) since January 01, 2020 and has been its Director since June 19, 2020. At Precigen, Dr. Sabzevari is leading discovery and development of the next generation of gene and cell therapies using precision technology to unmet medical needs in the areas of immuno-oncology, autoimmune disorders and infectious diseases. She served as President and Chief Executive Officer of PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.) since November 27, 2017. Dr. Sabzevari served as Senior Vice President of Human Therapeutics and Head of Research & Development of Precigen at Intrexon Corporation from July 2017 to December 2017. Dr. Sabzevari has extensive expertise in research and development of immunotherapy-based therapeutics as well as experience translating novel treatments from pre-clinical stage into the clinic. She co-founded and served as the Chief Scientific Officer of Compass Therapeutics LLC from 2015 to 2017. Dr. Sabzevari served as the Senior Vice President/Head of Immuno-Oncology, Global Research and Early Development at Merck Serono S.A. where her pioneering efforts led to the foundation of Merck Serono's immuno-oncology translational innovation platform for developing and advancing therapies, including cancer vaccines, cancer stem cell treatments and approaches to reset the immune system so that it is primed to eliminate cancer cells. From 2008 to 2014, Dr. Sabzevari served as Senior Vice President and Head of Immuno-Oncology, Global Research and Early Development at EMD Serono, Inc. From 1998 to 2008, Dr. Sabzevari also served as the Head of the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute (LTIB-NCI), where she led a research program focused on design, development and delivery of novel vaccines and immunotherapies for a range of human cancers. Dr. Sabzevari had been a Member of Scientific Advisory Board at Regen BioPharma Inc. since October 14, 2015 until 2021. Dr. Sabzevari is internationally recognized for her work in the field of immuno-oncology and her patient-first approach to drug discovery. Dr. Sabzevari received the Society for Immunotherapy of Cancer (SITC) Team Science Award for her work on the NCI Cancer Immunotherapy Program Team. She has been the recipient of Mass High Tech's Women to Watch Award and the PharmaVOICE 100 Award. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases. Dr. Sabzevari served as a Member of Advisory Board at Bio-Matrix Scientific Group, Inc.

Positions